PhosPrint has raised €500,000 to further develop its pioneering in vivo bioprinting technology for reconstructing bladder tissue during surgery, with a focus on enhancing patient outcomes.

Information on the Target

PhosPrint is a pioneering deep-tech startup based in Greece, specializing in in vivo laser bioprinting technology geared towards regenerative medicine. Recently, the company has successfully raised €500,000 in seed funding, primarily from Corallia Ventures TT, with support from angel investor Dr. Lars Rasmussen. The funding is designated for the first-in-human clinical trial of their innovative product, InvivoLPrint-U, which is the world's first bioprinter designed to reconstruct bladder tissue directly within a patient’s body during surgical procedures.

Currently, over 150,000 patients annually undergo bladder removal (cystectomy) globally due to cancer. Traditional reconstructive surgeries predominantly use intestinal tissue, leading to considerable side effects and complications. PhosPrint’s groundbreaking technology presents a solution by enabling urologists to print a fully functional neobladder using the patient's own healthy bladder cells, significantly reducing the risks associated with conventional surgeries.

Industry Overview in Greece

The biotechnology sector in Greece has been emerging steadily, with significant advancements in areas such as pharmaceutical development, medical devices, and regenerative medicine. The country benefits from a robust academic and resear